by MM360 Staff | Jun 3, 2025 | Uncategorized
Source: CureToday articles Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: ASCO Daily News Dr. John Sweetenham shares highlights from Day 4 of the 2025 ASCO Annual Meeting, including new research on maintenance therapy in small cell lung cancer and a virtual reality psychosocial intervention for patients undergoing hematopoietic stem...
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer. Read More
by Andrew (Drew) Rhoades; Francesca Castro, MS, RD, CDN | Jun 2, 2025 | Uncategorized
ORLANDO — A high-fiber, plant-based dietary intervention and nutritional counseling improved several risk factors for multiple myeloma, a study presented at the annual NUTRITION meeting showed.“Our study shows the power of nutrition in the preventive setting and...
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma. Read More
